Associated Papers
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
41152984 (PubMed )
Supplement: 13073_2025_1564_MOESM2_ESM.xlsx › Table_S5
CHD1 Promotes Sensitivity to Aurora Kinase Inhibitors by Suppressing Interaction of AURKA with Its Coactivator TPX2.
Li H et al.
Cancer Research, 2022
Targeting the protein-protein interface pocket of Aurora-A-TPX2 complex: rational drug design and validation.
Bhardwaj VK et al.
Journal of Biomolecular Structure & Dynamics, 2021
Gain of native conformation of Aurora A S155R mutant by small molecules.
Tanwar G et al.
Journal of Cellular Biochemistry, 2019
Mitotic regulators TPX2 and Aurora A protect DNA forks during replication stress by counteracting 53BP1 function.
Byrum AK et al.
The Journal of Cell Biology, 2019
Allosteric modulation of AURKA kinase activity by a small-molecule inhibitor of its protein-protein interaction with TPX2.
Janeček M et al.
Scientific Reports, 2016
Uncovering the genomic heterogeneity of multifocal breast cancer.
Desmedt C et al.
The Journal of Pathology, 2015
25850943 (PubMed )
Supplement: path0236-0457-sd9.xlsx › Table_S4
Ubiquitin-Mediated Degradation of Aurora Kinases.
Lindon C et al.
Frontiers in Oncology, 2015
A computational model for overcoming drug resistance using selective dual-inhibitors for aurora kinase A and its T217D variant.
Barakat KH et al.
Molecular Pharmaceutics, 2013
Computational investigation of cancer-associated molecular mechanism in Aurora A (S155R) mutation.
Kumar A et al.
Cell Biochemistry and Biophysics, 2013
A cancer-associated aurora A mutant is mislocalized and misregulated due to loss of interaction with TPX2.
Bibby RA et al.
The Journal of Biological Chemistry, 2009
Aurora kinase inhibitors as anticancer molecules.
Katayama H et al.
Biochimica Et Biophysica Acta, 0
Select a paper to view details